NxGen MDX
801 Broadway Avene NW
Suite 203
Grand Rapids
Michigan
49504
United States
Tel: 855-776-9436
Fax: 616-710-4667
Website: https://nxgenmdx.com/
Email: info@nxgenmdx.com
About NxGen MDX
NxGen MDx LLC is a leading clinical molecular diagnostics laboratory delivering highly accurate and precise genetic screening to detect genetic diseases or abnormalities to help guide family planning decisions for couples and their healthcare providers. Unlike other laboratories, NxGEN MDx's technology examines the entire gene rather than parts of the gene, giving families a comprehensive assessment of their true risk. NxGEN MDx is located in Grand Rapids, Michigan.YEAR FOUNDED:
2012
LEADERSHIP:
CEO: Alan Mack
JOBS:
Please click here for NxGen MDx job opportunities.
FOLLOW NXGEN MDX:
Tweets by NxGen MDx
11 articles about NxGen MDX
-
NxGen MDx Announces New Early Advantage Carrier Screening Panel
9/15/2021
NxGen MDx is taking an innovative approach to genetic carrier screening panel design by creating the Early Advantage Panel.
-
NxGen MDx Announces Partnership with Ginkgo Bioworks to Scale COVID Response through Pooled Testing in K-12 Schools
4/12/2021
Today, NxGen MDx announced a partnership with Concentric by Ginkgo to provide COVID-19 testing to congregate settings such as schools operating in-person or hybrid learning environments using a scalable and simple testing modality - pooled testing.
-
NxGen MDx has capacity to meet COVID-19 testing needs of nursing homes under new MDHHS order
6/22/2020
On June 15th, the Michigan Department of Health and Human Services issued an order regarding the testing of staff and residents at nursing homes statewide.
-
NxGen MDx announces the immediate launch and availability of their COVID-19 Test.
3/23/2020
To combat the lack of availability of tests, NxGen MDx announces the immediate launch and availability of their COVID-19 test.
-
NxGen MDx announces Urogenital Pathogens Tests with a turnaround of 24 hours
11/6/2019
NxGen MDx announced the launch of their Urogenital Pathogens Tests, a group of women's health tests.
-
NxGen MDx implements hereditary cancer panel
10/25/2018
NxGen MDx announced the creation of the NxGen MDx Hereditary Cancer Panel, which will test for variants in 32 genes known to cause certain forms of hereditary cancer.
-
Pyramidion Technology Group, Inc. ("PYTG") Announces Closing Its Acquisition With Established CBD Company NxGen Brands, LLC
10/24/2018
PYTG officially owns NxGen operations, brands, marketplace and is currently now a subsidiary of Pyramidion Technology Group, Inc.
-
NxGen MDx implements AMI tagging to track samples, preventing lab errors
7/11/2018
NxGen MDx announced the development and implementation of a new method of DNA tagging to track samples and prevent laboratory errors.
-
NxGen MDX Issues Revised Announcement Regarding National Aetna Contract
2/27/2017
-
NxGen MDX Publishes White Paper On Advantages Of Full-Gene Sequencing Over Genotyping For CF Carrier Screening
12/21/2016
-
NxGen MDX Announces The Move Of Their Non-Invasive Prenatal Test In-House
12/6/2016